A pacemaker keeps the heart beating at an adequate rate, but it does not stop heart failure from progressing or from being fatal. Heart failure is fundamentally a problem of the heart muscle weakening or stiffening so it cannot pump blood effectively, and a pacemaker addresses only one narrow piece of that puzzle: the electrical timing of heartbeats. In studies tracking pacemaker patients who died, heart failure has consistently ranked as the single most common cause of death, with one European study finding that over half of patients who received a pacemaker for heart failure symptoms ultimately died of heart failure anyway.
What a Pacemaker Actually Does and Does Not Do
A standard pacemaker monitors your heart’s electrical rhythm and delivers small electrical impulses when your heart rate drops too low or pauses too long. That is its entire job. It corrects bradycardia, which is a heart rate that is too slow, and it keeps the electrical signal moving through the chambers in a coordinated way. What it cannot do is make the heart muscle squeeze harder, reverse scarring or thickening of the heart wall, stop fluid from building up in the lungs and legs, or prevent the progressive decline that defines heart failure.
Heart failure is a condition in which the heart cannot pump enough blood to meet the body’s needs. It can result from coronary artery disease, high blood pressure, valve problems, infections, or genetic conditions. A pacemaker does nothing to address these underlying causes. It is like putting a metronome in front of a musician whose hands are too weak to press the keys: the timing may be perfect, but the music still will not come out right.
This distinction between electrical and mechanical heart function is where the common misconception lives. People hear “heart device” and assume it keeps the heart working in some comprehensive sense. In reality, a standard pacemaker is narrowly focused on rhythm. The heart muscle itself can continue to deteriorate, stiffen, or fail even while the pacemaker keeps the electrical signal firing on schedule.
How Common Is Heart Failure Death in Pacemaker Patients?
Heart failure is not just a possible cause of death in pacemaker patients; it is the leading one. A study analyzing causes of late death in patients with permanent pacemakers found that heart failure, stroke, and sudden cardiac death were the top three causes of death, in that order.1Semantic Scholar. Analysis of late cause of death in patients implanted with pacemakers Separately, a European study examining survival rates in pacemaker patients reported that among those who received their pacemaker specifically for heart failure symptoms, 54% of deaths were caused by heart failure itself.2PubMed. Survival rate and causes of death in patients with pacemakers: dependence on symptoms leading to pacemaker implantation
These numbers make an important point: a pacemaker does not remove heart failure from the equation. If anything, the patients who need pacemakers often already have structural heart disease that puts them at elevated risk for heart failure progression regardless of whether the device is working perfectly.
When a Pacemaker Can Actually Cause Heart Failure
Here is something that surprises many patients: in certain cases, the pacemaker itself can contribute to heart failure. This condition, called pacemaker-induced cardiomyopathy, occurs when prolonged pacing from the right ventricle disrupts the natural coordination between the two lower chambers of the heart.3PubMed Central. Pacemaker Induced Cardiomyopathy: An Overview of Current Literature Normally, both ventricles contract almost simultaneously. When a standard pacemaker stimulates only the right ventricle, the left ventricle contracts a fraction of a second later, creating a mismatch. Over months or years, this repeated uncoordinated squeezing can remodel the heart and weaken the left ventricle’s pumping ability.4Qanun Medika – Medical Journal Faculty of Medicine Muhammadiyah Surabaya. Understanding Pacing-Induced Cardiomyopathy: a mini review
Not everyone with a pacemaker develops this problem. Risk factors include being male, being older, having a wider electrical signal pattern on the heart tracing, and spending a high percentage of time being paced by the device.5PubMed. Incidence and predictors of pacemaker-induced cardiomyopathy with right ventricular pacing: a systematic review Doctors try to minimize pacing when possible, programming the device to let the heart’s own rhythm take over whenever it can. But for patients who are fully dependent on their pacemaker for every beat, the cumulative effect of right ventricular pacing can be a real concern.
This is one of the more counterintuitive aspects of pacemaker therapy: the very device meant to help the heart can, in some patients, nudge it toward failure. The condition is well recognized enough that cardiologists monitor for it with periodic echocardiograms and may recommend upgrading to a different type of device if the pumping function starts to decline.
Cardiac Resynchronization Therapy Changes the Picture
Not all “pacemakers” are equal, and this is where a more specialized device enters the conversation. Cardiac resynchronization therapy, or CRT, is a type of pacemaker designed specifically for heart failure patients. Instead of pacing only the right ventricle, a CRT device paces both ventricles simultaneously, restoring the coordinated squeeze that standard right ventricular pacing can disrupt. Randomized trials have shown that among patients with mild to moderate heart failure and a specific electrical pattern called left bundle branch block, CRT significantly reduces both death and hospitalization for heart failure.6PubMed Central. Mortality and Heart Failure After Upgrade to Cardiac Resynchronization Therapy
One of the landmark trials in this area, known as CARE-HF, followed patients for years and found that those who received CRT had roughly a 23% lower risk of death compared to those on medication alone.7PubMed. Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization-Heart Failure (CARE-HF) trial That is a meaningful improvement, but notice what it is not: it is not a cure. Even with CRT, a substantial number of patients still died during follow-up. CRT reduces the risk of dying from heart failure; it does not eliminate it.
Newer pacing approaches may push outcomes further. A technique called left bundle branch area pacing, which targets a specific part of the heart’s conduction system, has shown promising results in meta-analyses. Compared to traditional biventricular pacing, it was linked to a roughly 33% lower risk of heart failure hospitalization and a roughly 33% lower risk of death.8PubMed. Left bundle branch area pacing in heart failure: A systematic review and meta-analysis with meta-regression These are early findings and the technique is still gaining adoption, but they illustrate that where the pacemaker delivers its impulse matters enormously for heart failure outcomes.
A Pacemaker Is Not a Defibrillator
Another source of confusion is the difference between a pacemaker and an implantable cardioverter-defibrillator, or ICD. These devices look similar from the outside and are implanted in the same general location under the collarbone, but they serve different purposes. A pacemaker prevents the heart from going too slowly. An ICD monitors for dangerously fast or chaotic rhythms and delivers a shock to restore a normal heartbeat when one occurs.
Heart failure patients are at elevated risk for sudden cardiac death caused by these fast, irregular rhythms. A standard pacemaker cannot detect or treat these arrhythmias. A study examining sudden deaths in patients with cardiac devices found cases where patients died of documented fast, life-threatening rhythms while having only a pacemaker in place, when published guidelines would have recommended an ICD.9JAMA Internal Medicine. Sudden Death in Patients With Cardiac Implantable Electronic Devices In other words, having the wrong device for your condition can be fatal. Many heart failure patients need both pacing and defibrillation capability, which is why combination devices (CRT-D) that offer resynchronization therapy plus defibrillation are common in advanced heart failure.
Risk Factors That Predict Trouble
Among pacemaker patients, certain characteristics predict a higher risk of being hospitalized or dying from heart failure. Two factors consistently emerge as the strongest predictors in research: a left ventricular ejection fraction (a measure of how well the heart pumps) below 50%, and a specific electrical conduction pattern called left bundle branch block. In one study following pacemaker patients over about two years, those with reduced pumping function had roughly a five-fold higher rate of heart failure hospitalization or death, and those with left bundle branch block had about a 3.5-fold higher rate.10PubMed. Incidence and predictors of heart failure hospitalization and death in permanent pacemaker patients: a single-centre experience over medium-term follow-up
A separate study of patients who received a modern leadless pacemaker (a tiny self-contained device implanted directly inside the heart) found a similar pattern. About 18% of patients were hospitalized for heart failure during follow-up, and the strongest predictors were a history of atrial fibrillation and reduced pumping function.11European Heart Journal. Incidence and predictors of heart failure hospitalization in patients with the first marketed leadless pacemaker -micra VR The takeaway is that the pacemaker does not erase the underlying heart disease. Patients who already have weakened hearts before the pacemaker goes in remain at substantial risk for worsening heart failure afterward.
Medications Still Matter Enormously
One of the most underappreciated points in this entire discussion is that a device is not a substitute for medication. Heart failure drugs work on the root problem: they reduce the strain on the heart, lower fluid buildup, slow harmful hormonal pathways, and in some cases allow the heart muscle to partially recover. A pacemaker or even a CRT device works alongside these medications, not in place of them.
Yet studies consistently find that many patients with implanted devices are not receiving the full complement of recommended heart failure medications. One recent study found that among patients with ICDs and weak hearts, 58% were not on guideline-recommended drug therapy. When a targeted intervention got patients onto all four recommended drug classes, heart failure emergency visits and hospitalizations dropped substantially, a key blood marker of heart strain fell by about 25%, and the heart’s pumping function improved.12CJC Open. Guideline-Directed Medical Therapy in Patients After Implantation of Implantable Cardioverter Defibrillators to Improve Outcomes The device alone was not enough. The medications mattered at least as much, and probably more for some patients.
This gap between what guidelines recommend and what patients actually receive is a systemic problem. Sometimes patients and clinicians fall into a false sense of security after a device is implanted, assuming the hardware has the situation handled. The evidence says otherwise: optimizing medications after device placement measurably improves outcomes.
Complications That Can Make Heart Failure Worse
Beyond the direct issue of pacemaker-induced cardiomyopathy, pacemaker hardware can create mechanical problems that worsen heart function over time. One well-documented complication involves the leads, the thin wires threaded through veins into the heart. These leads pass through the tricuspid valve, which sits between the right atrium and right ventricle. Over time, the lead can interfere with how this valve closes, causing it to leak. Studies have found that lead-induced tricuspid valve leakage occurs in anywhere from about 7% to 39% of patients, and when it becomes significant, it worsens heart function and can increase long-term mortality.13PubMed Central. Treatment of severe tricuspid regurgitation induced by permanent pacemaker lead: Transcatheter tricuspid valve replacement with the guidance of 3-dimensional printing
Pacemakers can also detect irregular heart rhythms like atrial fibrillation that the patient may not even feel. These episodes of “silent” atrial fibrillation are common in pacemaker patients and are themselves a risk factor for heart failure progression and stroke. The ARTESiA trial studied patients with device-detected atrial fibrillation episodes and explored treatments to reduce their stroke risk, underscoring that these subclinical episodes are clinically meaningful and not just incidental findings.14Europace. Subclinical atrial fibrillation and the risk of heart failure: insights from ARTESiA
Remote Monitoring as an Early Warning System
Modern pacemakers and defibrillators can do something older models could not: continuously monitor the patient’s physiology and transmit data to the clinical team. These devices track things like fluid accumulation in the chest, heart rate patterns, patient activity levels, and how often irregular rhythms occur. Algorithms combine these signals into a composite score that can flag patients who are heading toward a heart failure flare before symptoms become obvious.15European Heart Journal. Fewer heart failure hospitalizations and improved survival with CIED algorithm-based remote monitoring on top standard of care
When clinical teams act on these early warnings by adjusting diuretics or other medications, the result can be fewer emergency hospitalizations and potentially better survival. This is a genuinely valuable capability, but it is worth keeping in perspective: the device is functioning as a sensor and alarm system, not as a treatment for heart failure. The treatment still comes from medications, lifestyle changes, and sometimes additional procedures. A pacemaker that detects worsening fluid buildup is useful only if someone responds to that alert.
Interestingly, pacemaker-detected physical activity data may also have diagnostic value. One study found that among pacemaker patients, each additional hour of daily physical activity detected by the device was associated with about a 15% reduction in the odds of having heart failure with preserved ejection fraction.16Journal of Clinical Exercise Physiology. THE ASSOCIATION BETWEEN PACEMAKER-DETECTED PHYSICAL AND HEART FAILURE WITH PRESERVED EJECTION FRACTION The pacemaker was not treating the heart failure; it was providing a window into the patient’s functional status that helped identify who was and was not developing problems.
Heart Failure with Preserved Pumping Function
Most of the discussion around heart failure and pacemakers centers on patients whose hearts pump weakly, but roughly half of all heart failure cases involve hearts that squeeze normally yet still cannot fill properly or relax between beats. This condition, heart failure with preserved ejection fraction, is surprisingly common among pacemaker patients. A screening program found that over a third of pacemaker patients met criteria for this form of heart failure.17Europace. Comparing diagnostic accuracy of HFA-PEFF score vs. ESC guidelines definition of heart failure with preserved ejection fraction: findings from a pacemaker systematic screening program Many of these patients had not been previously diagnosed.
A pacemaker offers essentially no direct treatment for this type of heart failure, since the problem is in how the muscle relaxes and fills rather than in the electrical timing. One study of patients hospitalized for heart failure with preserved ejection fraction found that those discharged on a beta-blocker who also had a permanent pacemaker had the lowest mortality, while those on a beta-blocker without a pacemaker had the highest.18Circulation. All-cause mortality for Patients with Preserved Ejection Fraction Heart Failure stratified by B-blocker Therapy and Presence of Permanent Pacemaker The likely explanation is that a pacemaker allows the heart to maintain an adequate rate even when beta-blockers slow it down, preventing dangerous drops in heart rate. The pacemaker is not treating the heart failure directly; it is acting as a safety net that makes certain medications more tolerable.
End-of-Life Decisions and Device Deactivation
For patients with terminal heart failure, the question eventually shifts from “can the device keep me alive?” to “should the device be turned off?” This is ethically and emotionally complex, and the answer differs depending on whether the device is an ICD or a pacemaker.
With an ICD, deactivation in terminal illness is widely recommended and relatively straightforward in principle. As a patient approaches death, the ICD may repeatedly shock a heart that is no longer capable of sustaining life, causing pain and distress without meaningful benefit. Medical societies generally agree that deactivating the shock function in this setting is appropriate and compassionate.19Medicina Clínica (English Edition). Deactivation of cardiac implantable electronic devices in palliative patients: When and how
Pacemaker deactivation is more controversial. Unlike an ICD shock, a pacemaker delivers no perceptible sensation. Turning it off does not relieve any discomfort. However, for patients who are fully dependent on the pacemaker for every heartbeat, deactivation would cause the heart rate to drop severely, potentially hastening death. Some clinicians and ethicists view this as ethically equivalent to withdrawing a ventilator in a patient who cannot breathe independently: a legitimate decision within the patient’s right to refuse treatment. A consensus statement from the Heart Rhythm Society and multiple partner organizations has endorsed a patient’s right to request pacemaker deactivation, erasing any ethical distinction between pacemaker and ICD withdrawal.20Journal of Pain and Symptom Management. Can You Die of Heart Failure If You Have a Pacemaker? In practice, though, many clinicians remain uncomfortable with the decision, and conversations about it often happen too late or not at all.21PubMed Central. Practical and ethical considerations in the management of pacemaker and implantable cardiac defibrillator devices in terminally ill patients
When Heart Failure Outpaces Every Device
For patients whose heart failure continues to worsen despite optimal medications, CRT, and every other intervention, the remaining options are a heart transplant or a mechanical pump called a left ventricular assist device. These pumps are implanted surgically and physically take over much of the heart’s pumping work, something no pacemaker can do. Candidates for these pumps, by definition, have severe heart failure symptoms despite having already tried all recommended therapies, including device-based treatments like CRT.22PubMed Central. Left ventricular assist device for end-stage heart failure: results of the first LVAD destination program in the Netherlands
The existence of these pumps as a next step illustrates the limits of pacemakers. When the heart muscle has deteriorated beyond what electrical therapy can support, the only remaining options involve physically augmenting or replacing the pump itself. A pacemaker, even the most advanced CRT device, cannot substitute for a heart that has lost the muscle strength to move blood. It can optimize the timing, coordinate the squeeze, and monitor for trouble, but the underlying engine has to have something left to work with.